Climate change increasing incidence of cataracts

Article

The increased level of ultraviolet (UV) rays in the Earth's atmosphere due to the depleted ozone layer is increasing the risk of cataract-induced blindness, according to a spokesman from the Fred Hollows Foundation.

The increased level of ultraviolet (UV) rays in the Earth's atmosphere due to the depleted ozone layer is increasing the risk of cataract-induced blindness, according to a spokesman from the Fred Hollows Foundation.

Andreas Mueller released the statement to mark World Health Day, whose theme this year was "Protecting health from climate change". The foundation, which was established in 1993 to treat cataracts in the developing world, claims that UV exposure is one of the top three causes of cataract, but that exposure can be minimized by simple protective measures such as wearing sunglasses and wide-brimmed hats.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.